Abstract:Kazuki Hamada, 1 Keiji Oishi, 2 Yoriyuki Murata, 2 Tsunahiko Hirano, 1 Kazuto Matsunaga 1 1 Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan; 2 Department of Medicine and Clinical Science, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan Correspondence: Kazuto Matsunaga Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan Tel/Fax +81-836-85-3123 Email In severe asthma with type 2 (T2) inflammation, biologics targeting key mediators of T2 inflammation, including interleukin (IL)-5, IL-4/IL-13, and immunoglobulin (Ig)E, remarkably improve the management of severe asthma, providing new insights into the clinical course of asthma such as disease modification and broad modulation of T2 inflammation. Once severe asthma has become a "controllable" condition, the question of discontinuation of biologics arises due to cost and side effects. The studies on discontinuing biologics in asthma demonstrate that some of patients successfully discontinue biologics, indicating that it is a feasible option in a subset of patients. Incorporating the evidence of discontinuation, we propose the criteria for the discontinuation of biologics. Our proposed criteria for the discontinuation of biologics consist of an absence of asthma symptoms (asthma control questionnaire [ACQ] score 19), no asthma exacerbations, no use of oral corticosteroids, normalized spirometry (forced exhaled volume in 1 second [FEV 1 ] ≥ 80%), suppressed T2 inflammation (blood eosinophil counts < 300 μL and fractional exhaled nitric oxide [FeNO] < 50 ppb), and control of asthma comorbidities. Real-world evidence verified a subset of patients achieving highly well-controlled conditions after use of biologics, namely super-responders, who are candidates for the discontinuation of biologics. If super-responders meet all of the criteria, they are allowed to discontinue biological therapies. Our proposed algorithm may support physicians' treatment decisions for patients receiving biologics. Keywords: biologics, discontinuation, severe asthma, super-responder Asthma is among the most common chronic respiratory diseases worldwide for all age groups. 1 Severe asthma, a condition with uncontrolled symptoms and higher exacerbation rates despite medium- or high-dose inhaled treatments with a second controller (GINA step 4–5) with good adherence and inhaler technique, affects 3.7% of patients with asthma. 2 An estimated 70–80% of patients with severe asthma show evidence of type 2 (T2) inflammation, 3,4 which is clinically characterized by increased blood and airway eosinophils, elevated serum immunoglobulin (Ig)E, and fractional exhaled nitric oxide (FeNO) levels. Biologics targeting mediators of T2 inflammation (eg, IgE, interleukin [IL]-5, and IL-4/IL-13) have dramatically improved the management of severe asthma during the past decade, decreasing exacerbations and oral corticosteroid use. 5–10 In current guidelines, severe asthma patients with the T2 phenotype are eligible for biologics, accounting for 85% of severe asthma patients. 11 Recent advances in asthma management, such as the advent of biologics, have provided new insight into the clinical course of asthma such as disease modification and broad modulation of T2 inflammation. 12 However, responses to biologics vary among patients. 13–17 Some patients respond to biologics, while others do not, and predictors of a response remain to be elucidated. The high cost of biologics creates an economic problem in patients and healthcare systems, and some patients may have difficulty continuing them as a result. 18 Nonetheless, current guidelines provide no information about which patients with severe asthma should stop biologics despite addressing when and how they should be initiated. 1 A management goal in patients with severe asthma is well-controlled condition, which is defined as the absence of symptoms, optimized lung function, no use of oral corticosteroids (OCS), and no exacerbations. Although this goal is not achievable for all the patients receiving biologics, there may be cases in which biologics can be discontinued if tight asthma control is maintained over time. In our institution, we experienced two cases with severe asthma who achieved extremely well-controlled conditions after benralizumab (no exacerbations, no OCS use, absence of significant asthma symptoms, normalized lung function, suppressed T2 inflammation assessed by blood eosinophils, and frac -Abstract Truncated-

Clinical Characteristics of Patients and Factors Associated with Switching Biologics in Asthma

Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study

Characterization of Severe Uncontrolled Asthma in Japan: Analysis of Baseline Data from the PROSPECT Study

Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach

SWITCHING BIOLOGICS FOR ASTHMA

Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR

Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study

How I do it. Choosing the right biologic for the right patient with severe asthma

Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022: An Analysis of the International Severe Asthma Registry

Exploring Definitions and Predictors of Response to Biologics for Severe Asthma

Association between pre-biologic T2-Biomaker combinations and response to biologics in patients with severe asthma

Long-term safety, durability of response, cessation and switching of biologics

Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Response to Various Biologics in Patients with Both Asthma and Chronic Obstructive Pulmonary Disease

A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study

Real-world biologics response and super-response in the International Severe Asthma Registry cohort

Biologics in severe eosinophilic asthma treatment: four years of a single-centre follow-up

An Analysis of Biologic Therapies in Patients With Asthma and Chronic Rhinosinusitis

Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics